Aripiprazol - antipsychotikum s novým farmakodynamickým účinkem

Aripiprazol je antipsychotikum s novými farmakodynamickými vlastnostmi. Účinkuje jako parciální agonista dopaminergních a serotoninergních receptorů, zatímco dosud podávaná antipsychotika plně inhibovala dopaminergní přenos. V klinické praxi je podávání aripiprazolu provázeno nižším výskytem nežádoucích účinků, které bývají časté i při léčbě atypickými antipsychotiky (např. nárůst glykémie, cholesterolémie, prolaktinémie, tělesné hmotnosti, prodloužení QTc intervalu a extrapyramidové reakce). Klinické studie prokazují vyšší účinnost aripiprazolu ve srovnání s placebem a srovnatelnou účinnost s atypickými antipsychotiky v terapii pozitivních i negativních příznaků schizofrenie, schizoafektivních poruch, akutní mánie a psychotických projevů u demencí.

AROPIPRAZOL - ANTIPSYCHOTIC WITH A NEW PHARMACODYNAMIC EFFECT

Aripiprazol is an antipsychotic agent with new pharmacodynamic properties. It has a partial agonistic activity to dopaminergic and serotoninergic receptors while until now used antipsychotic agents fully inhibited dopaminergic transmission. In the clinical practice, use of aripiprazol is accompanied with significantly lower incidence of adverse drug reactions frequently observed also during the treatment with atypical neuroleptics (e. g. increase in glycemia, cholesterolemia, prolactinemia, body weight, QTc interval prolongation, extrapyramidal symptoms). Clinical studies document significantly higher efficacy of aripiprazol comparatively to placebo and similar efficacy to atypical neuroleptics in the treatment of positive and negative symptoms of schizophrenia, schizoaffective disorders, acute mania and of psychotic symptoms in dementia.

References

Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ. 2004; 329(7457): 75. Go to original source... Go to PubMed...
Švestka J. Nová (atypická) antipsychotika 2. generace. Remedia 1999; 9 (reprint): 366-386.
Hermann N, Mandami M, Lanctot K. Atypical Antipsychotics and Risk of Cerebrovascular Accidents. Am J Psychiatry 2004; 161: 1113-1115. Go to original source... Go to PubMed...
Švestka J. Aripiprazol - antipsychotikum nové generace s jen parciální agonizací dopaminových D2/D3 a serotoninových 5-HT1A receptorů. Psychiatrie 2003; 7 (4): 279-289.
Gupta S, Masand P. Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders. Ann Clin Psychiatry. 2004; 16(3): 155-166. Go to original source... Go to PubMed...
Gründer G, Medori M, Kungel M, McQuade R, Kikuchi T. Aripiprazol: Pharmacology of a new antipsychotic (abstract). Eur Arch Psychiatry Clin Neurosci 2002; 252 (suppl.1):51.
McGavin JK, Goa KL. Aripiprazol. CNS Drugs 2002; 16: 779-786. Go to original source... Go to PubMed...
Taylor DM. Aripiprazol. A review of its pharmacology and clinical utility. Int J Clin Pract 2003; 57: 49-54. Go to original source... Go to PubMed...
Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61: 123-136. Go to original source... Go to PubMed...
Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol. 2004; 19(6): 351-353. Go to original source... Go to PubMed...
Abou-Gharbia N, Saha AR, Iwamoto T, Lin C, Kujawa MJ. Meta-analysis of prolactin effects with aripiprazole (abstract). Schizophr Res 2003; 60 (suppl): 350. Go to original source...
Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004; 64 (20): 2291-2314. Go to original source... Go to PubMed...
Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidon vs placebo in patients with schizofrenia and schizoaffective disorders. Arch Gen Psychiatry 2003; 60: 681-690. Go to original source... Go to PubMed...
Jody D, Saha AR, Iwamoto T, Biswas D, Lin C, Marcus R, McQuade RD. Meta-analysis of weight-effects with aripiprazole (abstract). Eur Neuropsychopharmacol 2002; 12 (suppl. 3): 290. Go to original source...
Madhusoodanan S, Brenner R, Gupta S, Reddy H, Bogunovic O. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectr. 2004; 9(11): 862-867. Go to original source... Go to PubMed...
Swainston Harrison T, Perry CM Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder Drugs. 2004; 64(15): 1715-1736. Go to original source... Go to PubMed...
De Deyn PP, Auby P, Goyvaerts H, Beder C, Schneider LS, Mintzer JE. Aripiprazole for psychosis of Alzheimer´s disease. APA Annual Meeting, San Francisco, Abstract NR 2003; 136.
Cornblatt BA, Kern RS, Carson WH, Ali MW, Green MF. Neurocognitive effects of aripiprazole versus olanzapine in patiens with stable psychosis (abstract). Biol Psychiatry 2002; 51 (suppl.1): 165.
McQuade RD, Kujawa M, Saha A, Ingenito GG, Ali M, Arcgibald DG, Carson WH. Aripiprazole for long-term maintenance treatment of schizofrenia (abstract). Biol Psychiatry 2003; 53 (suppl.1):176. Go to original source...
De Deyn PP, Auby P, Goyvaerts H, Beder C, Schneider LS, Mintzer JE. Aripiprazole for psychosis of Alzheimer´s disease. APA Annual Meeting, San Francisco, Abstract NR 2003; 136.
Streim JE, McQuade R, Stock E, Goyvaerts H, beder C, Iwamoto T, Yamamoto Y. Aripiprazole for the treatment of institutionalized patients with psychosis of Alzheimer´s dementia. AGS 2004 Annual Meeting. Paper Abstracts JAGS 2004 (suppl 1): A39.
Bourin M, Lambert O, Guitton B. Treatment of acute mania-from clinical trials to recommendations for clinical practice. Hum Psychopharmacol. 2004 Nov 26 (in press). Go to original source... Go to PubMed...